HOME >> MEDICINE >> NEWS
A key to depression

PROZAC stimulates the birth of new brain cells in rats, say scientists from New Jersey. The finding gives clues to what causes depression in people, how drugs like Prozac relieve it and why the effect takes so long to kick in.

Just over a year ago, researchers showed that people grow new neurons all the time. This overturned a long-held belief that brain cells, unlike cells in other parts of the body, are not replaced when they die.

Barry Jacobs and Casimir Fornal at Princeton University put together findings from several different brain studies. They knew, for instance, that depressed people have a smaller hippocampus-a structure that is involved in learning and memory-than healthy people.

They also knew that chronic stress can slow neuron birth, or neurogenesis, in the brains of rodents. Stress is thought to contribute to depression. "A little light went on in my head," says Jacobs. "It just occurred to me that maybe this is what depression is all about."

Jacobs and Fornal went on to show that activating one type of receptor for the neurotransmitter serotonin in rats' brains increased the birth of neurons. So they decided to see if Prozac, which belongs to a class of drugs known as selective serotonin re-uptake inhibitors (SSRIs), would have the same effect. SSRIs prevent serotonin from being mopped up, leaving more of it around to transmit messages.

The team gave daily injections of Prozac to five rats for 21 days. Five control rats were injected with saline. During the final 7 days, they also gave the rats a chemical called BrdU, which labels new neurons. When they examined the rats' brains, 69 per cent more new neurons had appeared in the brains of the Prozac-treated rats compared with the controls.

Jacobs and Fornal believe that the waxing and waning of neurogenesis in the hippocampus may be an important factor in explaining why people slump into depression and why they recover with SSRIs. It may also explain why Prozac takes severa
'"/>

Contact: Claire Bowles
claire.bowles@rbi.co.uk
44-20-7331-2751
New Scientist
2-Nov-1999


Page: 1 2

Related medicine news :

1. Single mothers at higher risk for depression
2. Treating depression helps slow physical decline in older adults, study shows
3. Pregnant women should exercise to keep depression away
4. Even mild depression increases long-term mortality in heart failure
5. Mood elevating hormone may trigger depression and heart problems
6. Study reveals frequent non-guideline treatment of late-life depression
7. York study tests enhanced care for depression patients
8. Is caesarean section linked to postnatal depression?
9. Over-the-counter supplement appears effective in treatment of midlife-onset depression
10. Mothers depression associated with increased risk of childs antisocial behavior
11. Best treatment for mild or moderate depression unclear

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: key depression

(Date:8/3/2015)... ... 03, 2015 , ... Sensato and Divurgent ... Healthcare Systems” This three-day, highly interactive and immersive workshop, has been developed ... to the tactics, techniques and practices required to design and develop highly secure ...
(Date:8/3/2015)... ... , ... A July 13 article from The Daily Mail titled "Jab ... That Can Last 'For Five Weeks'" discusses the use of stem cells to ... that harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal ...
(Date:8/3/2015)... San Ramon, CA (PRWEB) , ... August 03, ... ... a leading global insurance brokerage firm, announced today that Joe Williams has joined ... business development, sales, and delivering HUB's differentiated service model to his clients. Mr. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
(Date:8/2/2015)... Provo, Utah (PRWEB) , ... August 03, 2015 ... ... and corporate training, will be attending and exhibiting at the Association for Healthcare ... August 7-8. , “We are pleased for the opportunity the AHDI conference ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 /PRNewswire/ ... primary and secondary endpoints in a phase III study ... in adult patients with chronic non-cancer pain. Naldemedine is ... This is the third Phase III trial in which ... Study results showed that a 0.2 mg tablet ...
(Date:8/3/2015)... Israel , August 3, 2015 ... it received the statistical analysis of results from a study ... the BVX-005 phase II trial which took place in 2012, ... not exist at the time of the study- in particular ... the epidemic in the United States ...
(Date:8/3/2015)... Minn. , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ... neuroblocking therapy to treat obesity, metabolic diseases and other ... has been appointed to the Board of Directors, ... a Class II Director until the 2018 annual meeting ... Ms. McDougal has served in an executive capacity ...
Breaking Medicine Technology:Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3
Cached News: